Protalix BioTherapeutics Net Tangible Assets

Protalix BioTherapeutics's net tangible assets stands at $67M as of March 2026. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Protalix BioTherapeutics reported $67M in net tangible assets versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Protalix BioTherapeutics's net tangible assets evolved across reporting periods, while the comparison chart places PLX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, net tangible assets is commonly used to spot outliers. Protalix BioTherapeutics's reading of $67M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.